Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development

Steven Ford;William E. Tente;

Publication

Article

October 15, 2001

BioPharm International

BioPharm International-10-01-2001

Volume14

Issue 10

Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development

Author(s):

Steven Ford,William E. Tente

by Steven Ford and William E. Tente Chimeric Therapies, Inc. Manufacturing processes for murine monoclonal antibodies (mMABs) used in therapeutic applications must address more safety concerns than those used for in vitro diagnostics. Adequate characterization helps ensure that the mMAb retains its functional integrity after more extensive processing.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Qualification of Network Components and Validation of Networked Systems

Statistical Tools for Setting In-Process Acceptance Criteria

Managing Your Career: Recruiter-Proof Your Organization

Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing: Part 1, Considerations for Technology Transfer and Commercial Development

Inside Washington: Crisis and Costs Grip Biotech Industry

Outsourcing Outlook

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!